Abstract 4241
Background
Chemo-resistance is one of the important causes of poor prognosis of gastric cancer patients, but the exact mechanism is still not very clear. The regulation of lncRNA and miRNA and its downstream target genes has become in focus of the field.
Methods
In this study, we performed lncRNA and miRNA microarray analysis of chemo-resistant cells (SGC7901/Oxaliplatin). Then, bioinformatics analysis, TaqMan real-time PCR, western blot, luciferase reporter gene assay, RNA co-immunoprecipitation, cell proliferation and apoptosis analysis were used to explicit the lncRNA-miRNA-mRNA pathway in gastric cancer chemo-resistance. Last, nude mice were used to verify the promotion of chemo-resistance in vivo.
Results
In this study, we identified a lncRNA-GC1, which was upregulated in chemo-resistant gastric cancer tissues and cells, and a miRNA-551b-3p, which was downregulated in chemo-resistant gastric cancer tissues and cells. Firstly, miR-551b-3p can directly bind to the non-coding region of dysbindin mRNA, thereby negatively regulating the expression of dysbindin which was involved in chemotherapy resistance in gastric cancer cells. Secondly, lncRNA-GC1 promotes chemoresistance in gastric cancer by competitively binding to miR-551b-3p to facilitate dysbindin expression in vitro and in vivo. Thirdly, the expression levels of lncRNA-GC1 were positively correlated with tumor size (P = 0.002), lymph node invasion (P = 0.001) and poor platinum response (P < 0.001). Kaplan-Meier curves show that patients with high lncRNA-GC1 expression exhibit poorer overall survival compared with those with low lncRNA-GC1 expression. Multivariate analysis indicated that lncRNA-GC1 serves as an independent prognostic factor for patients with gastric cancer (P = 0.001).
Conclusions
LncRNA-GC1-miRNA-551b-3p-dysbindin signaling pathway may serve as a predictor for oxaliplatin response and a potential therapeutic target for gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guo Xin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5638 - Incidence of Vascular Thromboembolism Events in Cancer Patients Receiving Immunotherapy: A Single Institution Experience.
Presenter: Laura Gutiérrez Sainz
Session: Poster Display session 1
Resources:
Abstract
5182 - High Incidence of Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma.
Presenter: Alaa Abufara
Session: Poster Display session 1
Resources:
Abstract
1504 - Weight Loss over Time in Non-Small Cell Lung Cancer: Results from a Landmark Analysis of 800+ Prospectively-Treated Patients
Presenter: Jennifer Le-rademacher
Session: Poster Display session 1
Resources:
Abstract
3972 - The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC).
Presenter: Salvatore Paiella
Session: Poster Display session 1
Resources:
Abstract
2313 - Impact of Timing and Technique of Gastrostomy Placement on the Outcome of Patients (pts) with Head and Neck Cancer (HNC)
Presenter: M Julia Lostes Bardaji
Session: Poster Display session 1
Resources:
Abstract
5219 - Clinical & nutritional determinants of quality of life in patients with incurable cancer
Presenter: Louise Daly
Session: Poster Display session 1
Resources:
Abstract
4075 - Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer
Presenter: In Gyu Hwang
Session: Poster Display session 1
Resources:
Abstract
4159 - Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts).
Presenter: Ilaria Trestini
Session: Poster Display session 1
Resources:
Abstract
1210 - Sarcopenia and pretreatment anemia as prognostic factors for patients with localized muscle invasive bladder cancer treated by neoadjuvant chemotherapy and radical cystectomy
Presenter: Emilien Billon
Session: Poster Display session 1
Resources:
Abstract
2490 - Gender effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of anamorelin (ANAM) in healthy volunteers and cancer patients with cachexia
Presenter: Stein Kaasa
Session: Poster Display session 1
Resources:
Abstract